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SIRT1, the most conserved mammalian NAD+-dependent protein deacetylase, plays a vital role in 
the regulation of metabolism, stress responses, and genome stability. However, the role of SIRT1 
in the multi-step process leading to transformation and/or tumorigenesis, as either a tumor 
suppressor or tumor promoter, is complex and maybe dependent upon the context in which SIRT1 
activity is altered, and the role of SIRT1 in tumor metabolism is unknown. Here we demonstrate 
that SIRT1 dose-dependently regulates cellular glutamine metabolism and apoptosis, which in turn 
differentially impact cell proliferation and cancer development. Heterozygous deletion of Sirt1 
induces c-Myc expression, enhancing glutamine metabolism and subsequent proliferation, 
autophagy, stress resistance and cancer formation. In contrast, homozygous deletion of Sirt1 
triggers cellular apoptotic pathways, increases cell death, diminishes autophagy, and reduces 
cancer formation. Consistent with the observed dose-dependence in cells, intestine-specific Sirt1 
heterozygous mice have enhanced intestinal tumor formation, whereas intestine-specific Sirt1 
homozygous knockout mice have reduced development of colon cancer. Furthermore, SIRT1 
reduction but not deletion is associated with human colorectal tumors, and colorectal cancer 
patients with low protein expression of SIRT1 have a poor prognosis. Taken together, our findings 
indicate that the dose-dependent regulation of tumor metabolism and possibly apoptosis by SIRT1 
mechanistically contributes to the observed dual roles of SIRT1 in tumorigenesis. Our study 
highlights the importance of maintenance of a suitable SIRT1 dosage for metabolic and tissue 
homeostasis, which will have important implications in SIRT1 small molecule activators/inhibitors 
based therapeutic strategies for cancers.
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Introduction
Tumor cells have unusually high demands of nutrients for survival and rapid growth 
compared to normal differentiated cells [1, 2]. Their preference for an extremely high rate of 
glycolysis in the presence of oxygen (aerobic glycolysis, “the Warburg effect” [3]) is 
considered a hallmark of cancer [4]. Many cancer cells also exhibit addiction to glutamine, a 
nonessential amino acid that is the most abundant in the body [5]. Both glucose and 
glutamine feed into multiple nodes of central metabolism, providing intermediates for 
synthesis of lipids, proteins and nucleic acids, thereby supporting cancer growth and 
proliferation [2]. Genetic factors, including Myc and p53, actively regulate cancer cell 
metabolic reprogramming. It has been increasingly recognized that a major impact of 
genetic mutations in cancer cells is to reprogram their metabolic pathways to maximize use 
of nutrients under various nutritional and stress conditions [2, 6, 7].
The most conserved mammalian NAD+-dependent protein deacetylase, SIRT1, is an 
important metabolic and stress sensor [8, 9]. However, its role in tumorigenesis remains 
unclear and inconclusive [10, 11]. SIRT1 promotes DNA repair through PARP1, XPC, and 
WRN, and represses inflammation and induces apoptosis through inhibition of NF-κB, 
STAT3, HIF-1α, and β-Catenin [12–14]. On the other hand, SIRT1 inhibits activities of 
tumor suppressors, such as p53, Rb, and PTEN, while stimulating oncogenic pathways 
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including Myc, Ras, and Akt, thereby promoting growth and survival of cancer cells. As a 
result, whether SIRT1 is an oncogene or tumor suppressor remains controversial [15, 16].
In the present study, we explored the possibility that SIRT1 regulates cancer development in 
a quantitative dose-dependent manner and assessed the impact of this dosage-dependence on 
colorectal tumorigenesis. We hypothesized that different SIRT1-regulated pathways have 
distinct sensitivities to changes of SIRT1 dosages. Pathways that are sensitive to 
environmental alterations, such as metabolic cascades and inflammatory pathways, are also 
hypersensitive to fluctuations of SIRT1 expression/activity. In contrast, pathways involved in 
cell fate determination, including p53-mediated cell apoptosis, will only be activated upon 
drastic variations of SIRT1 expression/activity. The distinct sensitivities of different 
pathways to SIRT1 dosages differentiate the outcomes in cancer cell proliferation and 
growth, contributing to observed dual functions of SIRT1 in tumorigenesis.
Results
SIRT1 exerts a dose-dependent effect on cell proliferation and tumor formation
To test our hypothesis, we first analyzed immortalized Sirt1 wild-type (Sirt1+/+, WT), 
heterozygous (Sirt1+/−, Het), and knockout (Sirt1−/−, KO) mouse embryonic fibroblasts 
(MEFs) (Figure 1A). When cultured in complete DMEM medium containing 25 mM 
glucose and 4 mM glutamine, Het MEFs proliferated significantly faster than WT and KO 
MEFs (Figure 1B), and this increased proliferation was repressed (rescued) by putting back 
WT SIRT1 protein but not a catalytic inactive mutant of SIRT1 (Figure S1A and S1B). Het 
MEFs also formed significantly more and bigger colonies compared to WT MEFs in a soft-
agar colony formation assay, whereas KO MEFs failed to form a significant number of 
colonies (Figure 1C). More strikingly, when injected subcutaneously into nude mice, Het 
MEFs readily developed into large tumors within 5–8 weeks, whereas tumor formation was 
minimal or undetectable from WT or KO MEFs (Figure 1D and S1C).
In line with above observations in vitro, in an Azoxymethane (AOM)/Dextran Sulfate 
Sodium (DSS)-induced colon cancer model, intestine-specific Sirt1 heterozygous deletion 
mice (Villin-Cre+/Sirt1flox/+, Sirt1 iHet) developed significantly more and larger tumors 
compared to those of control mice in colons, whereas Sirt1 homozygous deletion mice 
(Villin-Cre+/Sirt1flox/flox, Sirt1 iKO), consistent with a recent report [17], had a reduced 
number of colon tumors (Figure 1E). Histopathological analyses further revealed that 4 out 
of 12 analyzed control mice lacked a response to the AOM/DSS treatment at all. For those 
that developed tumors, some tumors had marked regenerative hyperplasia (Figure S1D). 
However, tumors from all analyzed iHet mice had clearly progressed beyond regenerative 
hyperplasia into neoplasia (Figure S1D). Most tumors from iKO mice, in contrast, were 
restricted to low-grade stages lacking regenerative hyperplasia (not shown). Taken together, 
our results confirmed our hypothesis that Sirt1 insufficiency but not complete deficiency 
enhances tumor development in vitro and in vivo.
Ren et al. Page 3
Curr Biol. Author manuscript; available in PMC 2018 February 20.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Haploinsufficiency of Sirt1 promotes cell proliferation through enhanced glutamine 
metabolism
SIRT1 is a well-established metabolic regulator [8, 9], we therefore investigated whether 
metabolic dysregulation, particularly elevation of aerobic glycolysis, plays a role in Sirt1 
haploinsufficiency-induced transformation. Indeed, compared to WT and KO MEFs, Het 
MEFs displayed increased glucose uptake/consumption, lactate production, and expression 
of several key genes involved in glycolysis and related pathways (Figure S2A–S2D). 
Furthermore, Het MEFs had an increased trend in their glycolytic capacity (Figure S2E) and 
significantly enhanced glucose-dependent mitochondrial respiration (Figure S2F). However, 
surprisingly, when cultured in a glucose-free medium, Het MEFs still proliferated 
significantly faster than WT and KO MEFs despite the reduction of proliferation of all three 
cells (Figure S2G), indicating that enhanced glucose metabolism is not essential for Sirt1 
haploinsufficiency-induced cell hyper-proliferation.
In addition to glucose, most cancer cells have enhanced glutamine catabolism. Through the 
actions of glutaminase, glutamate dehydrogenase (Gdh), and aminotransferases, glutamine 
converts into α-ketoglutarate and feeds into the tricarboxylic acid cycle to support cell 
bioenergetics and anabolic reactions [2]. As shown in Figure 2A, restriction of medium 
glutamine from 4 mM to 0.5 mM eliminated the growth advantage of the Het MEFs vs WT 
and KO MEFs, suggesting that Het MEFs may sustain their high proliferation by increasing 
glutamine metabolism. Consistently, Het MEFs had significantly enhanced glutamine-
dependent mitochondrial respiration (Figure 2B), a marked increase in their glutamine 
uptake but decrease in intracellular glutamate levels (Figure 2C and 2D), together with 
elevated levels of glutamine transporters Slc1a5 and Slc7a5, and Gdh (Figure 2E). 
Furthermore, compared to WT and KO MEFs, Het MEFs displayed an increased GDH 
activity (Figure 2F) and elevated cellular contents of two products of this reaction, ammonia 
(Figure 2G) and α-ketoglutarate (Figure 2H), suggesting that enhanced glutamine 
metabolism is the major underlying mechanism for SIRT1 haploinsufficiency induced cell 
hyper-proliferation.
In support of the notion that an increase in glutaminolysis/glutamine metabolism rather than 
in glycolysis/glucose metabolism drives the hyper-proliferation phenotype of Het MEFs, 
depletion of GDH by siRNAs (Figure S3D) reduced the proliferation rates of Het and WT 
MEFs but not that of KO MEFs (Figure 3A), despite the fact that GDH depletion repressed 
and eliminated the difference of the glutamine-dependent mitochondrial respiration in WT, 
Het, and KO MEFs (Figure 3B). This observation suggested that enhanced glutamine 
metabolism significantly contributes to proliferation of Het and WT MEFs but not that of 
KO MEFs. Instead, KO MEFs appeared to maintain their proliferation by extremely high 
glycolysis as revealed by the ECAR profiling (Figure S2E, KO).
Further colony formation assays (Figure 3C and S3A) confirmed that Het MEFs formed 
significantly more colonies while KO MEFs formed fewer colonies than WT MEFs in 
complete culture medium as observed previously (Figure 1C). Switching to a glutamine-
restricted medium, a glutamine-free medium, or a complete medium containing 50 μM of a 
GDH inhibitor, EGCG, abolished the ability of Het MEFs to form more colonies than WT 
MEFs. In contrast, Het MEFs maintained their high colony-formation ability after glucose 
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deprivation. Collectively, our findings demonstrate that haploinsufficiency of Sirt1 promotes 
glutamine metabolism, thereby inducing cell hyper-proliferation and colony formation.
Haploinsufficiency of Sirt1 regulates autophagy and apoptosis through enhanced 
glutamine metabolism
In addition to being a major nutrient source, glutamine also serves as a key regulator of 
autophagy. Glutamine-derived free ammonia has been reported to promote basal autophagy 
and protect cells from TNFα triggered cell death [18, 19]. Consistent with their enhanced 
glutamine metabolism (Figure 2 and Figure 3), Het MEFs displayed a striking enhancement 
in formation of autophagolysosomes (Acridine orange) and autolysosomes (MDC) (Figure 
4A and S3B), along with increased levels of an autophagosomal marker Lc3II and several 
essential autophagy factors in complete glutamine-containing medium compared to WT 
MEFs (Figure 4B and S3C). Particularly, the increased formation of Lc3II-autophagosomes 
in Het MEFs was abolished upon glutamine restriction (Figure 4C and 4D) or GDH 
depletion (Figure S3D), supporting the notion that the enhancement of autophagy in Het 
MEFs is mediated by elevated glutamine metabolism. Furthermore, Het MEFs were 
protected from cell apoptosis induced by etoposide, a DNA damage reagent (Figure 4E), and 
displayed a higher survival rate in complete medium upon the etoposide treatment (Figure 
4F). Depletion of glutamine abolished the protective effect provided by Sirt1 
haploinsufficieny (Figure 4F) in spite of comparable degrees of DNA damage induced by 
etoposide in cells with the same genotype in both media (Figure S3E).
Sirt1 KO MEFs, on the other hand, had reduced formation of autophagolysosomes and 
autolysosomes (Figure 4A and S3B), reduced levels of autophagic protein factors (Figure 4B 
and S3C), and increased sensitivity to etoposide induced cell death (Figure 4E, 4F, and S3E). 
Together, our results indicate that loss of one copy versus both copies of Sirt1 gene 
differentially impact autophagy and apoptosis.
Dose-dependent regulation of the c-Myc pathway and p53 activity by SIRT1
SIRT1 induce transcriptional reprogramming in response to environmental cues through 
modulating acetylation of transcription factors/cofactors [8, 9]. Microarray analysis of gene 
expression profiles from WT, Het, and KO MEFs suggested that the activities of several 
SIRT1 regulated factors/pathways, including p53, Wnt3a/β-catenin signaling, TNFα (NF-
κB) activity, and the mTOR-c-Myc network, may be differentially altered by deletion of one 
copy or both copies of Sirt1 gene (Figure S4). p53, β-catenin, p65 subunit of NF-κB, and c-
Myc are all known SIRT1 deacetylation substrates. While SIRT1 mediated deacetylation of 
p53, β-catenin, and p65 represses their transactivation, deacetylation of c-Myc increase its 
stability and activity [20].
Not surprisingly, the acetylation levels of c-Myc, p65, and p53 were all significantly 
increased in KO MEFs (Figure 5A and S3F). However, their acetylation levels were 
distinctly affected in Het MEFs. Single copy deletion of the Sirt1 gene failed to significantly 
induce the acetylation of p53, but it was sufficient to increase the acetylation of p65 (Figure 
5A and S3F). Single copy deletion of the Sirt1 gene also increased the expression of c-Myc 
(Figure 5A and S3F), as well as a few c-Myc downstream target genes involved in cell 
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growth and proliferation (Figure 5B). Additionally, several key metabolic genes that are 
transcriptional targets of c-Myc [6], including Glut1, Pdk1 Slc1a5, and Slc7a5, were highly 
induced in Het MEFs (Figure S2D and 2E). Consistent with the notion that increased c-Myc 
activities promote glutamine metabolism and subsequent cell proliferation [6, 21–23], 
knocking-down c-Myc in Het MEFs completely eliminated their growth advantage (Figure 
5C and 5D), suggesting that SIRT1 haploinsufficiency induced cell hyper-proliferation is 
likely due to increased expression of c-Myc.
Conversely, KO MEFs had increased formation of DNA double strand breaks (γ-H2AX) 
(Figure S3E), increased expression of apoptotic genes (Figure 5E), and elevated apoptosis 
(Figure 4E and 4F) upon etoposide treatment. We have previously shown that the enhanced 
sensitivity of KO MEFs to etoposide induced apoptosis is dependent on p53 [24]. This p53-
mediated hypersensitivity to genotoxic stress may be responsible for observed reduced 
transformation of KO cells. Taken together, our observations demonstrate that distinct 
impacts of Sirt1 dosages on metabolic, proliferating, and apoptotic pathways contribute to 
the observed dose-dependent regulation of cell metabolism and proliferation by Sirt1.
Heterozygous deletion of Sirt1 enhances expression of glutamine metabolism genes and 
c-Myc signaling in AOM/DSS-induced colon tumors
In agreement with our observations in immortalized MEFs (Figure 2 and 5), AOM/DSS 
treated colon tissues from Sirt1 iHet mice had significantly increased expression of genes 
involved in glutamine transport (Figure 6A), together with increased levels of c-Myc protein, 
mRNA, and target genes involved in cell growth and proliferation (Figure 6B–6D). Colon 
tumors from iKO mice, also consistent with observations in MEFs (Figure S3E), displayed 
enhanced apoptotic features (Figure S5A). Intriguingly, colon tumors from iHet mice also 
had higher levels of intestinal stem cell markers (Figure 6E and S5B), suggesting that 
colorectal tumorigenesis induced in iHet mice may also involve uncontrolled tumor stem cell 
expansion. Tumors from iHet mice also had increased levels of an autophagy marker Lc3II 
(Figure 6E) as observed in Het MEFs (Figure 4). Collectively, our observations suggest that 
heterozygous deletion of Sirt1 enhances glutamine metabolism and c-Myc signaling in 
mouse colon tumors.
Reduced expression of SIRT1 is associated with enhanced colorectal adenocarcinoma cell 
proliferation, colon cancer development, and poor prognosis in humans
To further test our hypothesis, we generated human SIRT1 WT, Het, and KO colorectal 
adenocarcinoma cell lines using the Crispr/Cas9 technology (Figure S6A–S6D). Consistent 
with our observations in immortalized Het MEFs, deletion of one copy of SIRT1 gene in 
DLD1 cell line led to hyper-proliferation in a glutamine-dependent manner (Figure 7A), 
indicating that an increase in glutamine metabolism underlies the hyper-proliferation 
phenotype of Het DLD1 cells just like Het MEFs. In contrast to KO MEFs, however, KO 
DLD1 cells displayed a hyper-proliferation phenotype in a glucose-dependent manner 
(Figure 7A), possibly due to a S241F mutation thereby inactivation of p53 protein in these 
cells [25–27]. Moreover, deletion of single copy of SIRT1 gene in DLD1 cells was sufficient 
to increase the expression of c-MYC, whereas acetylation of P53 was elevated only when 
SIRT1 was completely deleted (Figure 7B). Additionally, Het DLD1 cells had increased 
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expression of several genes involved in glutamine metabolism (Figure 7C), supporting the 
notion that haploinsufficiency of SIRT1 promotes glutamine metabolism and induces hyper-
proliferation in cancer cells.
Further analysis of SIRT1 gene alterations and expression in 1117 colorectal cancer samples 
collected in databases of The Cancer Genome Atlas (TCGA), Genentech, and Memorial 
Sloan Kettering Cancer Center (MSKCC) indicated that the vast majority (about 99%) of 
colorectal cancer patients had a normal SIRT1 gene, and no deletion of this gene was 
detected in any of these databases (Figure S6E and Table S1). Comparison of human SIRT1 
mRNA levels between colon tumors and normal samples from non-colorectal cancer 
individuals in the TCGA revealed that human SIRT1 levels were modestly but significantly 
reduced in colon tumor samples (Figure 7D), consistent with the notion that SIRT1 
insufficiency but not complete deficiency contributes to tumorigenesis.
Next we measured SIRT1 protein expression in colorectal tissue microarrays constructed for 
the North Carolina site of the Cancer Care Outcomes Research and Surveillance Consortium 
(CanCORS), a population-based prospective cohort study of colorectal and lung cancer [28–
30]. We included 348 colorectal cancer subjects with medical records data available and at 
least one tumor core with a minimum of 50 epithelial cells and unambiguous histology 
(Table S2). SIRT1 proteins were detected in both tumor tissue and tumor-adjacent colorectal 
tissue (Figure S6F), and no statistically significant difference was detected between 
expression in tumor tissue and tumor-adjacent tissue after stratifying by sex, race, age, or 
tumor stage (Table S3). In tumor tissue on a continuous H-score scale of 0–300, the cut point 
distinguishing low SIRT1 expression from high expression with the best model fit in terms 
of association with all-cause mortality was observed at a value of 234.415. When 
dichotomized at this cut point, subjects with low expression of SIRT1 (n=255) showed 
significantly lower post-surgery survival rates than patients with high expression of SIRT1 
(n=93) (Figure 7E, univariate analysis; multivariate adjusted HR 2.07, 95% CI 1.28, 3.35 in 
multivariate analysis). These results demonstrate that reduced tumor SIRT1 expression 
correlates with poorer prognosis in colorectal cancer patients.
Discussion
The association between SIRT1 dosages and distinct consequences in tumor development 
have been previously suggested [13, 31–33]. However, this dosage-dependence has not been 
systematically analyzed, and conflicting observations from mouse models with Sirt1 
heterozygous deletion and homozygous deletion have resulted in inconsistent views on 
SIRT1’s roles in tumorigenesis [15, 16]. Our study showed that SIRT1 regulates colon 
cancer formation in a dosage-dependent manner, and this effect is dependent on glutamine 
metabolism. Intriguingly, the dosage-specific role of SIRT1 has also been observed in other 
SIRT1-regulated biological processes. For example, we and others have previously reported 
that whole-body Sirt1 heterozygous mice were sensitive to high-fat diet induced obesity and 
metabolic abnormalities [34, 35], while whole-body Sirt1 knockout mice were protected 
from high-fat diet induced body weight gain and obesity (unpublished observations). 
Likewise, the dosage-dependent effect also occurs in Sirt1 overexpressing models. 
Transgenic mice with modest overexpression of Sirt1 were protected from diet and aging 
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induced metabolic dysfunctions and spontaneous tumorigenesis [36–39] and displayed a 
reduced incidence of tumors in several cancer models [12, 40]. On the other hand, massive 
overexpression or overactivation of SIRT1 resulting from loss of tumor suppressors, such as 
HIC1 and DBC1, promotes growth and survival of cancer [41, 42]. These observations were 
consistent with our hypothesis that different cellular pathways have distinct sensitivities to 
SIRT1 dosages, and strongly suggest that maintenance of a suitable SIRT1 dosage is critical 
for metabolic and tissue homeostasis.
In addition to activation of c-Myc signaling, Sirt1 Het MEFs and colon tumors from Sirt1 
iHet mice also displayed an elevated NF-κB pathway (Figure 5A and S7A–D). Increased 
NF-κB has also been shown to promote glutamine metabolism and subsequent cell 
proliferation [43]. Although knocking-down p65 failed to completely eliminate the growth 
advantage of Het MEFs in culture (Figure S7E), we cannot exclude the possibility that the 
hyperactivated NF-κB pathway partially contributes to Sirt1 insufficiency induced 
transformation and tumor growth.
Experimental Procedures
Animal studies
The intestinal-specific Sirt1 homozygous knockout mice (iKO, Villin-Cre+/Sirt1flox/flox) and 
their littermate Flox-2 controls (Villin-Cre−/Sirt1flox/flox) on a C57BL/6 background were 
generated previously [44]. Sirt1 intestinal-specific heterozygous knockout mice (iHet, Villin-
Cre+/Sirt1 flox/+) and their littermate Flox-1 controls (Villin-Cre−/Sirt1 flox/+) were generated 
by breeding Sirt1 iKO mice with WT C57BL/6J mice.
For AOM/DSS-colon cancer model, three-four month old mice injected with AOM (8 
mg/Kg bwt). One week later, mice were fed 2.5% DSS in drinking water for 7 days followed 
by a 14-day of recovery with regular drinking water for three cycles. H&E stained slides of 
colons were evaluated by a designated study pathologist. c-Myc immunohistochemistry was 
performed with an anti-c-Myc specific antibody (Abcam, Cat# 39688, Cambridge, MA). All 
animal experiments were conducted in accordance with guidelines of NIEHS/NIH Animal 
Care and Use Committee.
Seahorse analysis
Seahorse analyses were performed on a Seahorse XF Analyzer according to manufacturer’s 
instructions (Agilent Technologies, Santa Clara, CA). Briefly, cells were plated in a 24-well 
assay plate the day before the analysis in the complete medium to ensure 80–90% confluent 
on next day, cells were then washed and incubated in a freshly prepared XF assay medium 
containing either 25 mM glucose, 0 mM glutamine, and 1 mM sodium pyruvate for 
measurement of glucose-dependent mitochondrial respiration, 0 mM glucose, 4 mM 
glutamine, and 1 mM sodium pyruvate for measurement of glutamine-dependent 
mitochondrial respiration, or 1 mM sodium pyruvate and 2 mM glutamate for measurement 
of glycolysis. Final mitochondrial respiration (OCR) and glycolysis (ECAR) were 
normalized to total cell protein contents.
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Human studies
The analysis of human SIRT1 gene alterations in colorectal cancer was performed via http://
www.cbioportal.org/index.do, from four independent studies with total of 1117 colorectal 
adenocarcinoma samples. The human SIRT1 gene expression data from normal control 
subjects and colon cancer patients was obtained from the TCGA Pan-Cancer Synapse 
(https://www.synapse.org/Portal.html#!Synapse:syn300013/wiki/), with 155 colorectal 
cancer patients and 19 normal controls.
To assess the relationship of SIRT1 expression to cancer patient prognosis, SIRT1 protein 
levels were analyzed by immunohistochemistry (cat #2493, Cell Signaling Technology, 
Danvers, MA) in tissue microarrays constructed for the North Carolina site of CanCORS 
[28–30], with total of 348 colorectal cancer patients. Cox proportional hazards models were 
used to estimate the association between SIRT1 expression and time from surgery to all-
cause mortality adjusted for age, race, sex, tumor stage, and histologic grade, with censoring 
at 5 years after surgery. Multivariate models were run for both continuous and dichotomous 
SIRT1 expression. Multiple imputation was used to evaluate missing covariate data. A cut 
point to define dichotomous SIRT1 expression status was determined by a systematic search 
across continuous marker expression values for the cut point with the best model fit (lowest 
Bayesian Information Criterion statistic) as described previously [45]. The Institutional 
Review Board at the University of North Carolina at Chapel Hill approved the protocol. All 
subjects provided informed consent.
Statistical analysis
For clinical data, univariate survival was assessed using the Kaplan-Meier method, with 
survival of low and high SIRT1 expression groups compared using the logrank test. 
Univariate analyses were performed using SAS 9.3 (SAS Institute, Cary, NC). Other results 
are expressed as mean + standard error of mean (SEM) from at least three independent 
experiments or biological replicates, unless otherwise indicated in the figure legend. 
Significant differences between the means were analyzed by the two-tailed, unpaired, non-
parametric Mann-Whitney test. For all statistical tests, p-values less than 0.05 were 
considered statistically significant.
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Figure 1. Dosage-dependent effects of SIRT1 on cell proliferation and tumorigenesis
(A) Immortalized Sirt1 wild-type (WT), heterozygous (Het), and knockout (KO) MEFs.
(B) Het MEFs display an increased proliferation rate. Immortalized MEFs were cultured in 
complete DMEM medium, plated and counted (n=3 independent cell lines/genotype, 
**p<0.01, values are represented as mean + SEM).
(C) Het MEFs form more and larger colonies while KO MEFs fail to form any colonies in a 
soft agar colony formation assay (n=3 independent cell lines/genotype, *p<0.05, **p<0.01, 
values are represented as mean + SEM).
(D) Het MEFs readily form larger tumors in a xenograft model. Immortalized MEFs were 
injected subcutaneously into the flanks and back of host nude mice (Nu/J from Jax) and their 
tumorigenic potential was analyzed. n=3 independent cell lines/genotype, with total of 8 
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repeats/genotype. The tumor diameters were measured at the end of experiments and the 
volumes were calculated: tumor volume (mm3) = ½ × longest diameter2 × shortest diameter. 
Bars, 1 cm.
(E) Sirt iHet mice have enhanced while Sirt1 iKO mice have reduced formation of colon 
tumors in an AOM/DSS colon cancer model. Single-copy flox controls (Flox-1) and double-
copy flox controls (Flox-2) were used as controls. Left, Representative images of colon 
tumors, bars, 1 cm. Right, Colon tumor numbers. n=23 (Flox-1), 21 (iHet), 25 (Flox-2), 23 
(iKO) mice, **p<0.01, ***p<0.001.
Please also see Figure S1.
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Figure 2. Haploinsufficiency of Sirt1 promotes cell proliferation and glutamine metabolism
(A) MEFs of all three genotypes display comparable proliferation rates upon glutamine 
restriction. Cells were plated and relative survived cell numbers were measured by the 
MTS/PMS reagents. n=3 independent cell lines/genotype, **p<0.01, values are represented 
as mean + SEM.
(B) Het MEFs have enhanced glutamine-dependent mitochondrial respiration. n=5 technical 
repeats, ***p<0.001, values are represented as mean + SEM.
(C) Het MEFs have increased uptake of glutamine. n=3 independent cell lines/genotype, 
***p<0.001, **p<0.01, values are represented as mean + SEM.
(D) Cellular glutamate levels in WT, Het, and KO MEFs. n=3 independent cell lines/
genotype, **p<0.01, values are represented as mean + SEM.
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(E) Het MEFs have increased mRNA levels of key genes involved in glutamine metabolism 
in complete medium. Gls, Glutaminase; Gdh, glutamate dehydrogenase; Gpt2, glutamic 
pyruvate transaminase. n=3 independent cell lines/genotype, **p<0.01, values are 
represented as mean + SEM.
(F–H) Het MEFs have increased activity of GDH (F), ammonia production (G), and cellular 
α-ketoglutarate levels (H) when cultured in complete medium. n=3 independent cell lines/
genotype, **p<0.01, *p<0.05, values are represented as mean + SEM.
Please also see Figure S2.
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Figure 3. Haploinsufficiency of Sirt1 promotes proliferation and colony formation through 
enhanced glutamine metabolism
(A) Knocking down Gdh represses hyper-proliferation of Het MEFs. Cells were plated and 
relative survived cell numbers were measured by the MTS/PMS reagents. n=3 technical 
repeats, **p<0.01, *p<0.05, values are represented as mean + SEM.
(B) Knocking down Gdh represses glutamine-dependent mitochondrial respiration. n=5 
technical repeats with a different set of MEFs from those in Figure 2B, *p<0.05, values are 
represented as mean + SEM.
(C) The distinct colony formation abilities of WT, Het, and KO MEFs on soft agar are 
dependent on the status of glutamine metabolism. Representative images from one group of 
cells were shown. n=3 independent cell lines/genotype, **p<0.01, *p<0.05, values are 
represented as mean + SEM.
Please also see Figure S2 and S3.
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Figure 4. Haploinsufficiency of Sirt1 increases autophagy and stress resistance through 
glutamine metabolism
(A) Het MEFs enhances yet KO MEFs reduces formation of acidic autophagolysosomes 
(acridine orange staining, top three panels) and autolysosomes (Monodansylcadaverine 
staining, MDC, bottom nine panels) in complete glutamine-containing medium.
(B) Het MEFs have increased levels of protein factors involved in autophagy.
(C–D) The enhanced autophagy in Het MEFs is dependent on glutamine. Immortalized 
MEFs were cultured in medium containing 0.5 mM glutamine for indicated times and 
expression of Lc3II was analyzed by immuno-blotting (C) or immune fluorescence (D).
(E) Het MEFs are resistant, whereas KO MEFs are sensitive to etoposide-induced apoptosis 
in normal culture medium. Immortalized MEFs cultured in complete glutamine-containing 
medium were treated with vehicle DMSO or 10 μM etoposide for 48 hours.
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(F) Sirt1 dosage induced distinct sensitivities to etoposide are dependent on glutamine. 
Immortalized MEFs were treated with vehicle DMSO or 10 μM etoposide for 48 hours in 
DMEM medium containing 4 mM or 0 mM of glutamine. Cell survival ratios between 
Etoposide vs DMSO treated cells were analyzed as by the MTS/PMS reagents. n=3 
technical repeats, **p<0.01, values are represented as mean + SEM.
Please also see Figure S3.
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Figure 5. SIRT1 haploinsufficiency induces hyper-proliferation through c-Myc
(A) Acetylation and expression of different substrates of SIRT1 display distinct sensitivities 
to the Sirt1 gene dosage. Immortalized MEFs cultured in complete medium were treated 
with 5 μM TSA for 30 minutes, and the total and acetylation levels of indicated proteins 
were analyzed by immuno-blotting or immunoprecipitation followed by immuno-blotting. 
Please also see Figure S3F.
(B) Deletion of one copy of Sirt1 stimulates the c-Myc pathway (n=3 technical repeats, 
*p<0.05, values are represented as mean + SEM).
(C–D) Knocking down c-Myc represses hyper-proliferation of Het MEFs. Relative survived 
cell numbers were measured by the MTS/PMS reagents (n=5 technical repeats, ***p<0.001, 
**p<0.01, values are represented as mean + SEM).
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(E) Deletion of both alleles but not single allele of Sirt1 induces expression of p53 targets 
upon DNA damage. Immortalized MEFs cultured in complete medium were treated with 
DMSO or 10 μM etoposide for 6 hours, expression of indicated p53 targets were analyzed 
by q-PCR (n=3 technical repeats, *p<0.05, values are represented as mean + SEM).
Please also see Figure S3, S4 and S7.
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Figure 6. Heterozygous deletion of Sirt1 in mouse intestine enhances glutamine metabolism, 
inflammation, and c-Myc signaling in AOM/DSS-colon tumors
(A) Sirt1 iHet colon tumors have increased expression of glutamine transporters. n=6 mice/
genotype, *p<0.05, **p<0.01, values are represented as mean + SEM.
(B–C) Sirt1 iHet colon tumors have increased c-Myc expression. c-Myc protein levels were 
analyzed by immunohistochemistry (B) or immune-blotting (C). Bars in (B), 50 μm. (D) 
Sirt1 iHet colon tumors have increased expression of c-Myc and cell proliferation genes. 
n=6 mice/genotype, *p<0.05, **p<0.01, values are represented as mean + SEM. (E) Sirt1 
iHet colon tumors have increased protein levels of markers for intestinal stem cells and 
autophagy.
Please also see Figure S5.
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Figure 7. Reduced expression of SIRT1 is associated with enhanced colorectal adenocarcinoma 
cell proliferation, colon cancer development, and poor prognosis in humans
(A) Haploinsufficiency of SIRT1 promotes proliferation of DLD1 cells in a glutamine-
dependent manner. WT, Het, and KO DLD1 cells were cultured in complete RPMI1640 
medium containing 11 mM glucose and 2 mM glutamine (Complete), no glucose (Glucose-
free), or no glutamine (Glutamine-free), and cell numbers were counted as indicated times 
(n=2 independent clones/genotype, with 2 technical repeats each, *p<0.05, values are 
represented as mean + SEM).
(B) Different substrates of SIRT1 have distinct sensitivities to SIRT1 dosage in DLD1 cells. 
DLD1 cells cultured in complete medium were treated with 5 μM TSA for 30 minutes.
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(C) SIRT1 Het DLD1 cells have increased expression of genes involved in glutamine 
metabolism. DLD1 cells were cultured in complete medium or in glutamine-free medium for 
72 hours (n=3 technical repeats, *p<0.05, values are represented as mean + SEM).
(D) mRNA levels of human SIRT1 are reduced in colon tumor samples compared to normal 
colon samples from non-colorectal cancer individuals in TCGA database. The median, 
upper, and lower quartiles were plotted, and the Wilcox test is used to evaluate their 
significance (Tumor group n=155; Normal group n=19; **p=0.0018).
(E) Colorectal cancer patients with low expression of tumor SIRT1 have a poorer prognosis 
than those with high expression. Kaplan-Meier overall survival stratified by dichotomizing 
SIRT1 expression status in tumor tissues (n=255 low expression/93 high expression) on a 
continuous H-score scale of 0–300 at cut point with best model fit (234.415).
Please also see Figure S6 and Tables S1, S2, and S3.
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